|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
Thanks the new powerful HTS platform (BIOPLATFORMSCREENTM ) Thrombotargets Corporation has received the Orphan Drug Designation for TT- 103MH.
This Human recombinant protein, TT-103MH, is projected as a powerful coagulant agent that will be used in the treatment of non-life threatening mild-to-severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients.
Hemophilia is a hereditary genetic disease in which an essential clotting factor is either partly or completely missing. This causes a person with hemophilia to bleed for longer than normal.
Contactwww. Thrombotargets.com General: info@thrombotargets.com
|
|
|
|
